Targeting the MITF/APAF-1 axis as salvage therapy for MAPK inhibitors in resistant melanoma.
Carotenuto P, Romano A, Barbato A, Quadrano P, Brillante S, Volpe M, Ferrante L, Tammaro R, Morleo M, De Cegli R, Iuliano A, Testa M, Andreone F, Ciliberto G, Clery E, Troncone G, Palma G, Arra C, Barbieri A, Capone M, Madonna G, Ascierto PA, Lanfrancone L, Indrieri A, Franco B.
Carotenuto P, et al. Among authors: clery e.
Cell Rep. 2022 Nov 8;41(6):111601. doi: 10.1016/j.celrep.2022.111601.
Cell Rep. 2022.
PMID: 36351409
Free article.